Bionano Genomics, Inc.
corporate_fare Company Profile
Bionano Genomics, Inc. (NASDAQ:BNGO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for BNGO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for BNGO spans 8-K, 10-Q, S-3, 10-K.
Recent high-impact activity:
- Bionano Projects 56% Revenue Growth in FY27, EBITDA Break-Even by Q4 FY27
- Bionano Q2 revenue climbs 21%, but going concern warning persists as cash dwindles to $3.7M
- Bionano Q2 Revenue Jumps 21% to $8.2M, Guides FY26 Revenue to $31-33M
- Bionano Genomics Appoints Alex Hastie as Chief Scientific Officer
- Bionano's OGM Studies Surge 67% at ESHG 2026, Signaling Expanding Global Adoption
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,144,194 shares in BNGO as of the September 15, 2026 settlement, a 6.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 56.6% of BNGO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BNGO, detected from its recent SEC filings.
New Universal Shelf Registration Filed · Addresses Going Concern Warning
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →